We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
Read MoreHide Full Article
Moderna (MRNA - Free Report) ended the recent trading session at $198.88, demonstrating a +2.08% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.51%. At the same time, the Dow added 0.93%, and the tech-heavy Nasdaq gained 0.48%.
Shares of the biotechnology company have appreciated by 36.46% over the course of the past month, outperforming the Medical sector's loss of 3.38%, and the S&P 500's gain of 0.74%.
The investment community will be paying close attention to the earnings performance of Moderna in its upcoming release. The company is predicted to post an EPS of -$1.36, indicating a 166.67% decline compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $888.78 million, down 12.52% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$8.5 per share and a revenue of $2.11 billion, indicating changes of -17.08% and +8.31%, respectively, from the former year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Moderna. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.42% higher within the past month. Currently, Moderna is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 172, this industry ranks in the bottom 31% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
Moderna (MRNA - Free Report) ended the recent trading session at $198.88, demonstrating a +2.08% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.51%. At the same time, the Dow added 0.93%, and the tech-heavy Nasdaq gained 0.48%.
Shares of the biotechnology company have appreciated by 36.46% over the course of the past month, outperforming the Medical sector's loss of 3.38%, and the S&P 500's gain of 0.74%.
The investment community will be paying close attention to the earnings performance of Moderna in its upcoming release. The company is predicted to post an EPS of -$1.36, indicating a 166.67% decline compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $888.78 million, down 12.52% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$8.5 per share and a revenue of $2.11 billion, indicating changes of -17.08% and +8.31%, respectively, from the former year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Moderna. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.42% higher within the past month. Currently, Moderna is carrying a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 172, this industry ranks in the bottom 31% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.